Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
GUTS Stock Chart & Stats
$0.42
-$0.12(-5.94%)
At close: 4:00 PM EST
$0.42
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.41 - $3.03
Previous Close$1.96
Volume269.01K
Average Volume (3M)7.71M
Market Cap
$58.31M
Enterprise Value$14.36M
Total Cash (Recent Filing)$77.66M
Total Debt (Recent Filing)$62.18M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Apr 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding137,044,430
10 Day Avg. Volume18,428,760
30 Day Avg. Volume7,706,364
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.16
Price to Sales (P/S)964.47
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue4.79K
Enterprise Value/Gross Profit-50.03
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$5.00Price Target Upside1090.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Weight MaintenanceClinical data indicate Revita's duodenal mucosal resurfacing can maintain or further weight loss after stopping GLP-1 therapy, with randomized cohorts showing sustained weight stability versus sham, supporting a single-procedure durability narrative.
Preclinical Gene Therapy ProgressPreclinical results for RJVA-002 and other Rejuva candidates show dose-dependent, substantial weight loss in animal models with no reported adverse events, reducing scientific risk and supporting advancement toward clinical testing for non-chronic metabolic treatments.
Safety ProfileAnalyst highlights a favorable safety profile with no serious device- or procedure-related adverse events and no participant discontinuations, supporting tolerability across Revita and Rejuva programs.
Bears Say
Evidence Gap And Regulatory Execution RiskKey evidence remains limited for parts of the pipeline to animal studies, so human clinical benefit is unproven and future regulatory authorization and trial readouts are required, creating execution risk.
Statistical UncertaintySome randomized analyses showed a smaller-than-expected benefit that did not reach statistical significance, prompting analysts to adopt a more cautious outlook on efficacy.
Trial Conduct And GeneralizabilityProtocol exclusions for noncompliance and at least one site that negatively influenced outcomes introduce uncertainty about how broadly the trial results apply to the wider patient population.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.41 and its highest was $3.03 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $58.31M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 59 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.316 by -$0.394.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 137,044,430 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.316. Following the earnings report the stock price went down -0.885%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (1090.48% Upside)
$5.00 (1090.48% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 21.2%
Last 30 Days ▲ 21.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.60%
12-Months-Change
Fundamentals
Return on Equity
-518.40%
Trailing 12-Months
Asset Growth
-9.97%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
GUTS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Fractyl Health, Inc. is experiencing significant clinical and financial progress, particularly with the Revita procedure's promising results in sustaining weight loss post-GLP-1 therapy and robust financial positioning. However, the increased net loss and weight regain in the sham group highlight some challenges.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$5.00
▲(1090.48% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
16.27% Insiders
1.86% Mutual Funds
55.86% Other Institutional Investors
24.39% Public Companies and Individual Investors
Options Prices
Currently, No data available
---